In contrast, HER2-positive and triple-negative breast cancer (TNBC) patients accounted for 46.8% and 15.0% of the cohort, respectively, and demonstrated significantly higher pCR rates, in alignment with existing clinical evidence. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.